Association of plasma P-tau181 with memory decline in non-demented adults

Joseph Therriault,1,2 Andrea L. Benedet,1,2 Tharick A. Pascoal,1,2 Firoza Z. Lussier,1,2 Cecile Tissot,1,2 Thomas K. Karikari,3,4 Nicholas J. Ashton,3,4,5,6 Mira Chamoun,1,2 Gleb Bezgin,1,2 Sulantha Mathotaarachchi,1,2 Serge Gauthier,2 Paramita Saha-Chaudhuri,7,8 Henrik Zetterberg,3,4,9,10 Kaj Blennow3,4 and Pedro Rosa-Neto1,2; for the Alzheimer's Disease Neuroimaging Initiative†

† Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. Accessed 19 June 2021.

Alzheimer’s disease is the leading cause of dementia worldwide and is characterized by a long preclinical phase in which amyloid-β and tau accumulate in the absence of cognitive decline. In vivo biomarkers for Alzheimer’s disease are expensive, invasive and inaccessible, yet are critical for accurate disease diagnosis and patient management. Recent ultrasensitive methods to measure plasma phosphorylated tau 181 (p-tau181) display strong correlations with tau positron emission tomography, p-tau181 in CSF, and tau pathology at autopsy. The clinical utility of plasma-based p-tau181 biomarkers is unclear. In a longitudinal multicentre observational study, we assessed 1113 non-demented individuals (509 cognitively unimpaired elderly and 604 individuals with mild cognitive impairment) from the Alzheimer’s Disease Neuroimaging Initiative who underwent neuropsychological assessments and were evaluated for plasma p-tau181. The primary outcome was a memory composite z-score. Mixed-effect models assessed rates of memory decline in relation to baseline plasma p-tau181, and whether plasma p-tau181 significantly predicted memory decline beyond widely available clinical and genetic data (age, sex, years of education, cardiovascular and metabolic conditions, and APOEe4 status). Participants were followed for a median of 4.1 years. Baseline plasma p-tau181 was associated with lower baseline memory (β estimate: −0.49, standard error: 0.06, t-value: −7.97), as well as faster rates of memory decline (β estimate: −0.11, standard error: 0.01, t-value: −7.37). Moreover, the inclusion of plasma p-tau181 resulted in improved prediction of memory decline beyond clinical and genetic data (marginal $R^2$ of 16.7–23%, $\chi^2 = 100.81, P < 0.00001$). Elevated baseline plasma p-tau181 was associated with higher rates of clinical progression to mild cognitive impairment (hazard ratio = 1.82, 95% confidence interval: 1.2–2.8) and from mild cognitive impairment to dementia (hazard ratio = 2.06, 95% confidence interval: 1.55–2.74). Our results suggest that in elderly individuals without dementia at baseline, plasma p-tau181 biomarkers were associated with greater memory decline and rates of clinical progression to dementia. Plasma p-tau181 improved prediction of memory decline above a model with currently available clinical and genetic data. While the clinical importance of this improvement in the prediction of memory decline is unknown, these results highlight the potential of plasma p-tau181 as a cost-effective and scalable Alzheimer’s disease biomarker.

1 Translational Neuroimaging Laboratory, McGill University, Montreal, Canada
2 Department of Neurology and Neurosurgery, McGill University, Montreal, Canada
3 Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden
4 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
5 King’s College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
6 NIHR Biomedical Research Centre, London, UK

Received February 17, 2021. Revised March 30, 2021. Accepted April 01, 2021. Advance Access publication June 14, 2021
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Early and accurate identification of Alzheimer’s disease pathology is critical for clinical trial selection, disease diagnosis and increasingly, changes in clinical care. Currently, in vivo quantification of amyloid-β and phosphorylated tau, the core pathological hallmarks of Alzheimer’s disease, is performed with PET or with CSF assays. While these techniques have high sensitivity and specificity for detecting biological Alzheimer’s disease in vivo, they are limited by substantial cost, invasiveness and low availability, prohibiting widespread clinical use.

Recent advancements in plasma measurements of phosphorylated tau show high sensitivity and specificity for detecting biological Alzheimer’s disease in vivo, they are limited by substantial cost, invasiveness and low availability, prohibiting widespread clinical use. Biological Alzheimer’s disease is characterized by a preclinical period lasting over a decade in which detectable amyloid-β and tau accumulate in the absence of cognitive symptoms; in familial Alzheimer’s disease, plasma phosphorylated tau concentration starts to increase around 15 years prior to expected clinical disease onset. Therefore, there exists a promising therapeutic window to identify individuals with biological Alzheimer’s disease for disease-modifying trials. Furthermore, because clinical criteria for Alzheimer’s disease have limited sensitivity and specificity for Alzheimer’s disease pathology, the addition of plasma-based biomarkers of phosphorylated tau to clinical workups may provide information to physicians evaluating individuals with age-related cognitive impairment. Plasma assessments of phosphorylated tau may represent a scalable, cost-effective and minimally invasive clinical tool with the potential to improve dementia-related care globally.

Despite the promise of these measurements, large-scale studies of well-characterized cohorts are needed to determine the incremental prognostic information gained from...
plasma measures of phosphorylated tau. The goal of this study is therefore to determine associations between plasma measures of tau phosphorylated at threonine (p-tau181) with rates of memory decline over up to 5 years in individuals participating in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a longitudinal multicentre observational study. We also investigated associations between plasma p-tau181 concentration and risk of clinical progression to dementia, in comparison to currently available clinical, cardiovascular and genetic information.

**Materials and methods**

**Study design and population**

The ADNI is an ongoing prospective cohort study that continues to recruit participants (ClinicalTrials.gov number: NCT01231971); this study included all individuals with available samples for analyses (accessed June 2020). In this study, we assessed cognitively unimpaired (CU; n = 509) and amnestic mild cognitive impairment (MCI; n = 604) individuals from the ADNI cohort who underwent plasma evaluation of p-tau181 and neuropsychological evaluations. Cognitively normal controls had a Clinical Dementia Rating of 0. MCI subjects had a Clinical Dementia Rating of 0.5, with the memory box score of at least 0.5, with general cognitive performance sufficiently preserved such that a diagnosis of dementia cannot be made by the study physician. The ADNI study was approved by the Institutional Review Boards of all of the participating institutions. Informed written consent was obtained from all participants at each site. Exclusion criteria included neurological diseases other than Alzheimer’s disease, known structural brain abnormalities and history of head trauma followed by persistent neurological symptoms. Full information regarding the ADNI inclusion and exclusion criteria can be accessed at http://adni.loni.usc.edu/ (last accessed June 19th, 2021). Information about access to ADNI data is provided at http://adni.loni.usc.edu/data-samples/access-data/ (last accessed June 19th, 2021).

**Exposures**

Clinical predictor variables were age, sex, education and APOEe4 genotype, as well as a composite cardiovascular and metabolic conditions score. These predictors were selected because of their availability in clinical settings. The cardiovascular and metabolic conditions score was determined as the sum of seven conditions proposed by the US Department of Health and Human Services as indicators of vascular health. These seven cardiovascular and metabolic conditions were hypertension, hyperlipidaemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes and stroke, many of which have been identified as contributors to dementia incidence. This cardiovascular and metabolic condition score was selected because it has been employed in recent longitudinal population-based studies assessing the relationships between Alzheimer’s disease biomarker status and memory decline and other studies of ageing and Alzheimer’s disease. Quantification procedure of plasma p-tau181 concentrations has been described previously. Assay performance information is provided in the Supplementary material.

**Outcomes**

This study’s primary outcome was a numeric memory composite z-score, selected because memory decline is one of the most common concerns with advancing age and an increasingly frequent reason for seeking clinical care in the elderly. Memory tests consisted of the Wechsler Memory Scale-Revised Logical Memory-II (delayed recall), the Rey Auditory Verbal Learning Task (delayed recall) and the Alzheimer’s Disease Assessment Scale 13-Cog (ADAS-Cog). These tests were selected because they were widely available across ADNI 1, ADNI GO, ADNI 2 and ADNI 3. Each test was converted to z-scores using the mean and standard deviation (SD) of the CU subjects’ baseline evaluation. The composite memory z-score was calculated based on the mean of these three z-scores. Approximately 68% of the CU elderly population had baseline memory composite z-scores within 1 SD of the mean.

**Statistical analyses**

Statistical analyses were performed using the R statistical software. Baseline demographic and clinical data were assessed using t-tests and χ² tests. Continuous predictor variables were z-scored to reduce the influence of variables with large ranges and to aid in the interpretation of coefficients. In primary analyses, we employed a dichotomized (normal/abnormal) value for plasma p-tau 181 because normal/abnormal values are frequently employed in clinical practice to guide patient management and are often required for clinical trial enrolment. Individuals were classified into groups of high/low plasma p-tau based on a published threshold of 17.71. This threshold was obtained from the least distance from (0.1) from a Receiver Operating Characteristic (ROC) curve comparing Amyloid-β negative CU elderly individuals with Amyloid-beta positive Alzheimer’s disease dementia individuals as described in Ref. Because dichotomizing continuous biomarkers presents with conceptual limitations, we repeated mixed-effect analyses using continuous measures of plasma p-tau 181.

We employed mixed-effects models with a continuous memory composite z-score as the outcome with terms for both memory effects at the screening visit, and longitudinal change in memory. Because of previous reports
describing non-linear trajectories of cognitive decline,\textsuperscript{22} we fit quadratic terms for age and time from baseline. The statistical significance of these terms was determined using log-likelihood tests. Time from baseline (years), plasma p-tau181 levels and their interaction were included as fixed effects. Model outputs for plasma p-tau181 provide information about baseline performance and model outputs for the interaction of plasma p-tau181 with time provide information about the longitudinal change (slope). Participants (intercept) and time from baseline visit (slope) were included as random factors.

There were two main steps in statistical modelling in the present study. In the first step, we built a basic clinical prediction model that included readily available clinical information: age, sex, years of education, cardiovascular and metabolic conditions, and APOE\textsuperscript{e4} status. While APOE\textsuperscript{e4} is not presently recommended for the diagnosis and clinical management of patients with neurodegenerative disease,\textsuperscript{14} it was assessed in order to compare our study with a recent longitudinal study assessing the relationships between Alzheimer’s disease biomarker status and memory decline,\textsuperscript{16} which included APOE\textsuperscript{e4} status as potentially available clinical information. In this basic clinical model, covariates were evaluated as to whether they were related to memory score at baseline, as well as longitudinal change in memory z-score. In the second step, we built a p-tau181-enhanced model. The p-tau181-enhanced model contained every significant term in the basic clinical model, with the addition of two terms: (i) a dichotomized measurement of baseline plasma-derived p-tau181 to predict baseline memory composite z-score and (ii) interaction between dichotomized baseline plasma-derived p-tau181 with time, to predict longitudinal change in memory z-score. A detailed description of the procedure to build the clinical and p-tau181 models is provided in the Suppplimentary material.

To compare the basic clinical model with the p-tau181-enhanced model, we compared the marginal $R^2$ value for each generalized mixed-effect model. Marginal $R^2$ values correspond to the proportion of the variance that is explained by fixed effects (and does not include variance explained by random effects). We used analysis of variance to compare whether the two models were statistically different. Finally, we report Akaike Information Criterion and Bayesian Information Criterion values for both models.

In exploratory analyses, we added intracranial volume-adjusted hippocampal volume as a neurodegeneration biomarker to the clinical model to determine the incremental information provided by plasma p-tau181 with a more established biomarker. MRI acquisition and processing in ADNI has been described previously (http://adni.loni.usc.edu/methods/mri-tool/mri-pre-processing/, last accessed June 19th 2021). A previously validated adjusted hippocampal volume cut-off of $-0.63$ cm$^3$ was employed to categorize subjects as neurodegeneration positive or negative.\textsuperscript{23}

**Survival analyses: Cox proportional hazard models**

We employed two separate Cox proportional hazards models to assess time to change in diagnosis from (i) a baseline diagnosis of CU to MCI and (ii) a baseline diagnosis of MCI to dementia. Both models were adjusted for APOE\textsuperscript{e4}, age, sex and years of education. All participants were censored at their last follow-up visit. Hazard ratios (HR) are reported. The assumption of proportional hazards was tested using Schoenfeld residuals, non-linearity was assessed using Martingale residuals, and the presence of potentially influential outliers was assessed with Deviance residuals. Survival analyses used binarized values of p-tau181 using the same threshold described above.

**Data availability**

Data employed in this study are publicly available and can be accessed through the Laboratory of Neuro Imaging (LONI) database (http://adni.loni.usc.edu/data-samples/access-data/#access_data; last accessed June 19th 2021).

**Results**

**Demographics**

Demographic and clinical information is summarized in Table 1. Of the 1113 individuals in the study, 535 (48\%) were women. The mean (SD) age in the CU group was 73.75 (5.83); the mean (SD) of the MCI group was 72.19 (7.47). Subjects with MCI were more likely to be APOE\textsuperscript{e4} carriers. At baseline, individuals with MCI had lower memory composite z-scores than CU individuals. Moreover, individuals with MCI had higher baseline levels of plasma p-tau181. Participants were followed for a median (SD) of 4.1 (1.34) years.

**Prediction of memory scores**

Plots of group-level memory z-score trajectories over 5 years are presented in Fig. 1A. Figure 1B presents memory z-score trajectories over 5 years grouped by plasma p-tau181 status. In both CU and MCI individuals, positive plasma p-tau181 status was associated with worse baseline memory composite z-scores ($\beta$ estimate: $-0.49$, SE: 0.06, $t$-value: $-7.97$, $P < 0.001$), as well as faster memory decline over 5 years ($\beta$ estimate: $-0.11$, SE: 0.01, $t$-value: $-7.37$, $P < 0.001$). Summary statistics of regression coefficients are summarized in Table 2. Summary statistics for models of CU and
Table 1 Demographic and key characteristics of the sample

|                  | CU        | MCI       | P-value |
|------------------|-----------|-----------|---------|
| No.              | 509       | 604       |         |
| Age, year, mean (SD) | 73.75 (5.83) | 72.19 (7.47) | <0.0001 |
| Female, no. (%)   | 260 (51)  | 257 (42.5)| 0.004   |
| Education, year, mean (SD) | 16.55 (2.58) | 16.03 (2.8) | <0.0001 |
| Racial category   |           |           |         |
| American Indian/Alaskan Native | 1 (0)    | 1 (0)     |         |
| Asian             | 9 (1.7)   | 8 (1.1)   |         |
| Black             | 25 (4.9)  | 17 (3)    |         |
| Hawaiian/Pacific Islander | 0 (0)    | 2 (0)     |         |
| More than one     | 11 (2.2)  | 6 (1)     |         |
| White             | 460 (90.3)| 563 (93)  |         |
| Unknown/not reported | 2 (0)    | 7 (1)     |         |
| Ethnic category   |           |           |         |
| Not Hispanic/Latinx | 484 (95) | 580 (96) |         |
| Hispanic/Latinx   | 19 (3.7)  | 19 (3.2)  |         |
| Unknown/not reported | 4 (0.7)  | 5 (0.8)   |         |
| APOE ε4 carriers, % | 145 (28.5) | 289 (47.8) | <0.0001 |
| MMSE, mean (SD)   | 29.02 (1.2)| 27.25 (3.31)| <0.0001 |
| Baseline memory z-score (SD) | 0.00 (0.66) | -1.16 (0.99) | <0.0001 |
| Baseline plasma p-tau181, pg/mL, mean (SD) | 16.25 (9.99) | 19.01 (12.07) | <0.0001 |

Mean and standard deviation (SD) are provided for continuous variables and n and % are provided for dichotomous variables. P-values indicate values assessed with two-sided independent samples t-tests for each variable except sex and APOE ε4 status, where contingency chi-square tests were performed. P-values reported are for comparisons to CU subjects.

CU = cognitively unimpaired; MCI = mild cognitive impairment; MMSE = mini-mental state examination; p-tau181 = phosphorylated tau at threonine 181.

MCI groups separately are presented in Supplementary Tables 2 and 3.

Utility of plasma p-tau181 in predicting memory decline

We next compared the incremental utility of adding plasma p-tau181 to the clinical model (consisting of age, sex, education and APOE ε4 genotype, as well as a composite cardiovascular and metabolic conditions score) for predicting memory decline. The p-tau-enhanced model offered significant improvement in the prediction of memory decline over the basic clinical prediction model ($\chi^2 = 100.81$, likelihood ratio test $P < 0.001$), with marginal $R^2$ increasing from 16.7% (clinical model) to 23% (p-tau181-enhanced model). Comparative model statistics are presented in Table 3. Elevated plasma p-tau181 was associated with lower memory scores at baseline ($\beta$ estimate: $-0.49$, SE: 0.06, $t$-value: $-7.97$, $P < 0.001$). Furthermore, plasma p-tau181 positivity was associated with faster longitudinal memory decline ($\beta$ estimate: $-0.11$, SE: 0.01, $t$-value: $-7.37$, $P < 0.001$). Non-dichotomized values of plasma p-tau181 yielded a similar improvement in predicting memory decline, with marginal $R^2$ values increasing to 22.2% in the p-tau181-enhanced model. Comparative model statistics for continuous measures of plasma p-tau181 are presented in Supplementary Table 4, and summaries of regression coefficients when employing continuous measures of plasma p-tau181 are presented in Supplementary Table 5. Subgroup analyses of individuals with subjective cognitive decline are described in the Supplementary material. Analyses comparing the incremental utility of adjusted hippocampal volume are reported in the Supplementary material.

Survival analyses

We conducted survival analyses to determine associations between plasma p-tau181 status and clinical progression from CU to MCI, or from MCI to dementia. Survival analyses were corrected for age, sex, years of education, cardiovascular and metabolic conditions, and APOE ε4 status. Elevated plasma p-tau181 was associated with increased risk of clinical progression (HR = 2.12, 95% CI: 1.69–2.67, $P < 0.001$) over 5 years in all subjects (Fig. 2). In CU individuals, plasma p-tau181 also predicted progression to MCI over 5 years (HR = 1.82, 95% CI 1.2–2.8, $P = 0.005$). In individuals with MCI, plasma p-tau181 predicted progression to dementia over 5 years (HR = 2.06, 95% CI: 1.55–2.74, $P < 0.001$). Summary statistics for survival models are presented in Supplementary Table 6.

Discussion

This study presents evidence of associations between plasma biomarkers of p-tau181 and prediction of memory decline over more readily available clinical and genetic information. Higher levels of plasma p-tau181 were related to decreased memory function at baseline. Elevated plasma p-tau181 at baseline also predicted greater memory decline over up to 5 years. A plasma p-tau181 biomarker evaluation provided a significant increase in the prediction of memory decline beyond genetic, clinical and demographic information. Similar results were observed for both continuous and dichotomized values of plasma p-tau181. Taken together, this longitudinal multicentre study provides evidence for the clinical utility of plasma p-tau181 measurements, which are cost-effective, accessible and scalable.

Memory dysfunction is a common reason for seeking medical care in individuals with advancing age.3,18 Plasma p-tau181 levels were associated with a significant improvement in the prediction of cognitive decline over the clinical model consisting of age, sex, education and APOE ε4 genotype, as well as a composite cardiovascular and metabolic conditions score (Marginal $R^2 = 16.7\%$ versus 23% by adding plasma p-tau181). This increase in predictive information is comparable to a recent population-based study that reported a 5% increase in the prediction of memory decline over an average of 4.8 years when employing a combination of amyloid-PET, tau-PET and MRI together to classify non-demented individuals.
based on amyloid-β/tau/neurodegeneration (A/T/N) biomarker status. While our study was conducted in a highly selected cohort, which may confer optimistic performance for plasma p-tau181, this is a highly encouraging finding given the substantially lower cost and invasiveness of a blood draw as compared to two PET scans and an MRI scan.

Elevated levels of plasma p-tau181 were associated with increased risk of progression from CU to MCI or Alzheimer’s disease (HR = 1.82, 95% CI 1.2–2.8), as well as from MCI to Alzheimer’s disease (HR = 2.06, 95% CI: 1.55–2.74). These HR are somewhat lower than HR reported in CSF studies of clinical progression from CU to MCI or Alzheimer’s disease dementia of 5.21% or 17.7% for the progression from MCI to Alzheimer’s disease dementia. Future studies assessing the benefit of the lower invasiveness of plasma p-tau181 in comparison to the higher predictive value conferred by CSF will be needed to further determine the clinical utility of plasma p-tau181.

Plasma p-tau181 is a biomarker specific for Alzheimer’s disease tau pathology and correspondingly does not capture the full spectrum of the A/T/N framework as proposed by the National Institute of Aging-Alzheimer’s Association (NIA-AA). Accordingly, combining plasma assays of p-tau181 with mass spectrometry-based plasma assays of amyloid-β may result in superior predictions of cognitive and functional decline, especially over longer time periods, as well as superior specificity for Alzheimer’s disease. Indeed, a recent study reported that

Figure 1 Association of baseline plasma p-tau181 with 5-year cognitive trajectories. Mixed-effect models predicting memory score at the baseline visit (intercept), as well as longitudinal change in memory score (slope). (A) Average 5-year memory composite z-score decline trajectories for CU individuals (top) and individuals with MCI (bottom). At the group level, CU individuals declined a mean of 0.1 in memory composite z-score, and individuals with MCI declined a mean of 0.2 in memory composite z-scores. (B) Five-year memory composite decline trajectories stratified based on baseline plasma p-tau181 status. In CU individuals (top), baseline plasma p-tau181 was not associated with memory performance at baseline (β estimate: −0.1, SE: 0.06, P = 0.13), though it predicted faster longitudinal decline over 5 years (β estimate: −0.01, SE: 0.004, P = 0.014). In individuals with MCI, elevated plasma p-tau181 was associated with over half a standard deviation lower memory performance at baseline (β estimate: −0.44, SE: 0.07, P < 0.001), as well as faster rates of decline over 5 years (β estimate: −0.12, SE: 0.02, P < 0.001) compared to individuals without elevated plasma p-tau181 at baseline.
plasma p-tau181 was only associated with neurodegeneration and cognitive decline in individuals with elevated amyloid-β.27 Likewise, the inclusion of a plasma-based neurodegeneration biomarker such as plasma neurofilament light chain,28 while not specific for Alzheimer’s disease, may also improve prognostic capacity. In fact, a recent longitudinal study from the BioFINDER and ADNI cohorts reported that a model including plasma neurofilament light chain and p-tau181 was associated with superior prediction of clinical progression from MCI to dementia.29 Given recent advancements in blood-based Alzheimer’s disease biomarkers, a single blood sample provides the ability to assess multiple aspects of the Alzheimer’s disease pathological processes, namely amyloid-β, tau and neurodegeneration. This constitutes a promising advantage in contrast to neuroimaging, for which three separate scans would be required to determine a patient’s A/T/N imaging biomarker status,26 in turn related to substantially increased cost, patient burden and decreased accessibility.

Early evidence suggests that plasma p-tau181 becomes abnormal approximately 6 years after an individual reaches abnormal levels of amyloid-β,30 in line with established biomarker models from autosomal-dominant31 and sporadic32 Alzheimer’s disease in which amyloid-β abnormality precedes tau abnormality. Recent studies have also associated p-tau181 with cortical thinning as well as hypometabolism,33 indicating that plasma p-tau181 may help track neurodegenerative processes in Alzheimer’s disease. However, due to the novelty of plasma-based p-tau measurements, several questions remain.10 Studies assessing the positive predictive value of abnormal p-tau181 levels in relation to more established tau biomarkers such as tau-PET34,35 will be required to increase confidence in the significance of plasma p-tau181 concentrations at the individual level.

Our study fits within an emerging body of literature in which plasma concentrations of p-tau181 are associated with cognitive decline. In a recent longitudinal study from the ADNI and BioFINDER cohorts, plasma p-tau181 concentrations predicted clinical progression to dementia from MCI.29 Furthermore, a recent longitudinal study also conducted in the ADNI cohort observed associations between plasma p-tau181 and changes in the Preclinical Alzheimer Cognitive Composite in individuals without cognitive impairment.27 Taken together, these studies provide evidence for the feasibility of plasma p-tau181 in the individual-level prediction of cognitive decline.

Our study must be interpreted in the context of several limitations. The most important limitation of our study is the selected nature of the ADNI cohort, which constitutes individuals motivated to participate in a study on brain ageing and Alzheimer’s disease and excludes known neurodegenerative diseases other than Alzheimer’s disease. The potential benefit of all diagnostic tests varies with respect to the prevalence of the target condition in the tested population. Plasma p-tau181 measurements are specific for Alzheimer’s disease-type tau4–6; therefore, its predictive power is limited to predicting Alzheimer’s disease-related cognitive decline. Because multiple neurodegenerative processes can result in cognitive decline,16,37 plasma p-tau181 will by definition only capture variability in cognitive decline associated with Alzheimer’s disease and will likely be less helpful for predicting cognitive decline in other neurodegenerative diseases. It is therefore important to emphasize that our results cannot be generalized to memory clinic, primary care or population-based cohorts. Future clinical trials in those settings will be needed to determine the utility of plasma p-

---

### Table 2 Regression coefficients of p-tau model

| Beta estimate | SE | t-value | P-value |
|---------------|----|---------|---------|
| (Intercept)   | -0.07 | 0.06 | -1.32 | 0.19 |
| Baseline age  | 1.00 | 0.47 | 2.10 | 0.04 |
| Baseline age² | -1.10 | 0.47 | -2.33 | 0.02 |
| Time (years)  | 0.09 | 0.02 | 4.79 | <0.000001 |
| Time (years²) | -0.02 | 0.00 | -7.17 | <0.000001 |
| Sex, male     | -0.30 | 0.06 | -4.94 | <0.000001 |
| APOE ε4 status, carrier | -0.43 | 0.06 | -7.04 | <0.000001 |
| Education, years | 0.18 | 0.03 | 6.08 | <0.000001 |
| Baseline cardiovascular and metabolic conditions | -0.07 | 0.03 | -1.95 | 0.05 |
| Plasma p-tau181 status | -0.49 | 0.06 | -7.97 | <0.000001 |
| Sex × times (years) | -0.01 | 0.01 | -0.38 | 0.70 |
| Baseline age × time (years) | -0.04 | 0.01 | -5.29 | <0.000001 |
| APOE ε4 status × time (years) | -0.09 | 0.01 | -6.02 | <0.000001 |
| Plasma p-tau181 status × time | -0.11 | 0.01 | -7.37 | <0.000001 |

Summary statistics for p-tau181-enhanced model, in which plasma p-tau181 status is dichotomized based on a threshold of 17.71. Similar results were obtained when using continuous measures of plasma p-tau181 (summarized in Supplementary Table 5).

---

### Table 3 Comparative model statistics

| No. of parameters | AIC | BIC | Log-likelihood | Deviance | Marginal R² |
|-------------------|-----|-----|----------------|----------|-------------|
| Clinical model    | 16  | 7779.5 | 7880.1 | -3873.8 | 7747.5 | 16.7% |
| P-tau enhanced model | 18  | 7682.7 | 7795.9 | -3823.3 | 7645.7 | 23% |

Five-year model comparison for all subjects. Summary model statistics of clinical model and p-tau-enhanced model. The p-tau-enhanced model offered a significantly better prediction of memory decline (R² = 100.811, df = 2, P < 0.000000001).

AIC = Akaike Information Criterion; BIC = Bayesian information criterion.
The results of our study provide a proof-of-concept that plasma p-tau181 may be useful. However, the specificity of plasma p-tau181 may be beneficial for differential diagnosis, and for screening individuals for disease-modifying trials. Despite the fact that Alzheimer’s disease is the leading cause of dementia worldwide, investigating the utility of plasma p-tau181 in population-based cohorts and primary care settings is an important next step in determining the utility of this biomarker. Another limitation is the lower proportion of minorities, specifically Black individuals, who participated in this study, a problem reported in other large-scale Alzheimer’s disease biomarkers studies and pharmaceutical trials. Replicating the present study in a more representative sample is an important step in determining the utility of plasma measures of p-tau181, especially because of recent studies indicating modest relationships between race and tau biomarkers. It is important to emphasize that as a marker of tau pathology, plasma p-tau181 is not intended to be a complete substitution of the A/T(N) Alzheimer’s disease biomarker framework, which also includes amyloid-β and neurodegeneration biomarkers. While the goal of this study was to evaluate the additional prognostic value of recently developed plasma measures of p-tau181, we anticipate that with widespread availability of ultrasensitive and specific plasma-derived amyloid-β and neurodegeneration biomarkers, predictive power over clinical and genetic information would likely increase. Moreover, the recent development of plasma measures of tau phosphorylated at other sites such as p-tau217 and p-tau231 deserve investigation. Finally, we wish to emphasize that the thresholds for ‘elevated’ plasma p-tau181 are specific to this study population and future studies are needed to validate appropriate thresholds, including the possibility of more than one threshold (i.e. low/intermediate/high).

Supplementary material
Supplementary material is available at Brain Communications online.

Acknowledgements
Data collection and sharing for this project were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euroimmun; F. Hoffmann-La Roche; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development, LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). Public sector contributions are managed by the University of California, San Diego, in collaboration with ADNI public sector partners.

Figure 2 Association of elevated plasma p-tau181 with clinical progression over 5 years. (A) Kaplan–Meier survival curves for progression from CU to MCI among participants with positive or negative plasma p-tau181 at baseline. Cox proportional hazard models revealed that elevated baseline plasma p-tau181 was associated with an elevated risk of clinical progression to MCI (HR = 1.82, 95% CI: 1.2–2.8, P = 0.005) in CU elderly individuals. (B) Kaplan–Meier survival curves for progression from MCI to dementia among participants with positive or negative plasma p-tau181 at baseline. Cox proportional hazard models revealed that elevated baseline plasma p-tau181 was associated with a higher risk of developing dementia (HR = 2.06, 95% CI: 1.55–2.74, P < 0.001) in MCI individuals. Cox proportional hazard models were adjusted for age, sex, years of education, APOE ε4 status and cardiovascular and metabolic conditions.
Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson Johnson Pharmaceutical Research &; Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

**Funding**

J.T. is funded by the Canadian Institutes of Health Research doctoral scholarship. This work is supported by the Canadian Institutes of Health Research (CIHR) (MOP-11–51-3), the Alzheimer’s Association (NIRG-12-92090, NIRP-12-259245), Fonds de Recherche du Québec–Santé (Chercheur-Boursier and 2020-VICO-279314) and the Weston Brain Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862) and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017–00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809–2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärfnfonden, Sweden (#FO2017-0243), the Swedish State Support for Clinical Research (#ALFGBG-715986) and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236).

**Competing interests**

K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. No other authors declare any relevant conflicts of interest.

**Contributors**

J.T., A.L.B., T.A.P., P.S.-C. and P.R.N.: Study concept and design, manuscript draft. T.K.K. and N.J.A.: Performed blood assay development. C.T., F.L., M.C., G.B. and S.M.: designed and implemented image processing protocols and performed quality control. S.G., P.S.C., H.Z. and K.B.: study supervision, critical revision of the manuscript for intellectual content.

**References**

1. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.
2. Jack CR, Bennett DA, Blennow K, et al.: Contributors. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14(4):535–562.
3. Rabinovici GD, Gaitsonis C, Appar C, et al. Association of Amyloid Positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cog- nitive impairment or dementia. JAMA. 2019;321(13):1286–1294.
4. Karikari TK, Pascoa TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422–433.
5. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26(3):379–386.
6. Thijssen EH, La Joie R, Wolf A, et al.; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387–397.
7. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772–710.
8. O’Connor A, Karikari TK, Poole T, et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: A longitudinal cohort study. Mol Psychiatry. 2020;181:1–10. DOI:10.1038/s41380-020-0838-x.
9. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266–273.
10. Gauthier S, Thiriaux J, Pascoa T, Rosa-Neto P. Impact of p-tau181 and p-tau217 levels on enrolment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. Expert Rev Neurother. 2020;20(12):1211–1213. doi:10.1080/14737571.2020.1841637.
11. Jack CR. The transformative potential of plasma phosphorylated tau. Lancet Neurol. 2020;19(5):373–374.
12. Rocca WA, Gazzuola RL, Smith CY, et al. Bilateral oophorectomy and accelerated aging: cause or effect? J Gerontol A Biol Sci Med Sci. 2017;72(9):1213–1217. doi:10.1093/gerona/glx026.
13. Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multi-morbidity in a geographically defined American population: Patterns by age, sex, and race/ethnicity. Mayo Clin Proc. 2014;89(10):1336–1349.
14. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–2734.
15. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446.
